Nephromag (Buffered Phosphate Solution | Mertiatide)

Buffered Phosphate Solution, the active ingredient in Nephromag, is a pharmaceutical preparation presented as an intravenous solution for IV use. It is employed to manage phosphate balance in clinical settings where electrolyte control is required. GNH USA supplies Nephromag as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and pharmacies worldwide.

Nephromag provides buffered phosphate for conditions that require intravenous electrolyte management.

- Hypophosphatemia: helps restore normal serum phosphate levels in patients with low phosphate. - Renal replacement therapy: used as part of dialysis solutions to maintain phosphate balance. - Major surgery: administered to support electrolyte homeostasis during extensive operative procedures.

Nephromag may be associated with a range of adverse reactions following intravenous administration.

Common Side Effects: - Mild nausea - Transient headache - Local irritation at infusion site - Slight increase in serum phosphate - Mild hypotension during rapid infusion - Temporary dizziness

Serious or Rare Side Effects: - Hyperphosphatemia leading to calcium precipitation - Severe hypocalcemia - Allergic anaphylactic reaction - Acute renal failure in susceptible patients

Nephromag should be used with careful clinical monitoring.

- Serum phosphate monitoring: check levels before and during therapy. - Calcium balance: watch for hypocalcemia, especially when co‑administered with calcium salts. - Renal function: assess kidney performance prior to infusion. - Infusion rate: administer slowly to reduce risk of hypotension. - Contraindications: avoid in patients with known hyperphosphatemia. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Nephromag may interact with other agents affecting electrolyte balance.

Major Interactions (Avoid): - Calcium supplements: can precipitate calcium phosphate. - Iron dextran: may enhance phosphate binding and reduce efficacy.

Moderate Interactions (Monitor Closely): - Loop diuretics: may alter renal phosphate handling. - Vitamin D analogues: influence calcium‑phosphate metabolism. - Antacids containing aluminum or magnesium: affect phosphate absorption.